New Data Bolster Tecentriq Bid To Be First Adjuvant Immunotherapy In NSCLC

US FDA Decision Expected 1 December

 
• By Andrew McConaghie
  
Roche_Logo_Glass
Roche's Tecentriq is trailing Merck's Keytruda in advanced NSCLC, but could be first approved in an adjuvant setting.

More from Business

More from Scrip